Provided by Tiger Trade Technology Pte. Ltd.

Minerva Neurosciences

3.25
-0.5500-14.47%
Post-market: 3.570.3200+9.85%17:39 EST
Volume:97.28K
Turnover:338.10K
Market Cap:22.73M
PE:-1.75
High:3.80
Open:3.77
Low:3.25
Close:3.80
52wk High:12.46
52wk Low:1.15
Shares:6.99M
Float Shares:5.44M
Volume Ratio:2.07
T/O Rate:1.79%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.8533
EPS(LYR):0.1901
ROE:-675.09%
ROA:-25.82%
PB:-0.66
PE(LYR):17.10

Loading ...

Minerva Neurosciences Expands Board Amid Fundraising Effort

TIPRANKS
·
Nov 19

BRIEF-Minerva Neurosciences Appoints Dr. Inderjit Kaul To The Company’S Board Of Directors

Reuters
·
Nov 19

Minerva Neurosciences Appoints Dr. Inderjit Kaul to Board of Directors

Reuters
·
Nov 19

Minerva Neurosciences Appoints DR. Inderjit Kaul to the Company’s Board of Directors

THOMSON REUTERS
·
Nov 19

Minerva Neurosciences Files Initial Beneficial Ownership Statement for Director Inderjit Kaul

Reuters
·
Nov 19

Minerva Neurosciences Inc. Announces Date for Upcoming Annual Stockholders Meeting

Reuters
·
Nov 15

Minerva Neurosciences Reports Q3 2025 Financial Results

TIPRANKS
·
Nov 11

Minerva Neurosciences (NERV) Gets a Hold from H.C. Wainwright

TIPRANKS
·
Nov 10

Minerva Neurosciences Is Maintained at Neutral by HC Wainwright & Co.

Dow Jones
·
Nov 06

Minerva price target lowered to $4 from $5 at H.C. Wainwright

TIPRANKS
·
Nov 06

Minerva Neurosciences reports $2.7 mln Q3 net loss

Reuters
·
Nov 05

Minerva Neurosciences Q3 EPS $(0.36) Misses $(0.35) Estimate

Benzinga
·
Nov 05

BRIEF-Minerva Neurosciences Q3 Net Income USD -2.744 Million

Reuters
·
Nov 05

Minerva Neurosciences Secures $80 Million Financing and Plans Phase 3 Roluperidone Trial

Reuters
·
Nov 05

Minerva Neurosciences Q3 Operating Expenses USD 2.844 Million

THOMSON REUTERS
·
Nov 05

Minerva Neurosciences Inc: on a Path Forward to Advancing Roluperidone for Treatment of Negative Symptoms of Schizophrenia

THOMSON REUTERS
·
Nov 05

Minerva Neurosciences: R&D,Admin Costs May Rise, but We’re Well Positioned to Fund Phase 3, Nda Resubmission and Launch Prep for Roluperidone in US

THOMSON REUTERS
·
Nov 05

Minerva Shares Soar on $200 Million Financing for Schizophrenia Drug Trial

Dow Jones
·
Oct 21

Shares of Minerva Neurosciences More Than Double After Co Secures up to $200 Million in Private Placement, Last up 163.2%

THOMSON REUTERS
·
Oct 21

Why Is Minerva Neurosciences Stock (NERV) Up 165% Today?

TIPRANKS
·
Oct 21